The Medical Letter on Drugs and Therapeutics
Sonidegib (Odomzo) for Basal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the hedgehog pathway inhibitor sonidegib (Odomzo – Novartis) for oral treatment of locally advanced basal cell carcinoma that cannot be treated with surgery or radiation or has recurred following such treatment. Vismodegib (Erivedge), another oral hedgehog pathway inhibitor, was approved earlier for the same indication and also for treatment of metastatic basal cell carcinoma.1

STANDARD TREATMENT — Basal cell carcinomas that cannot be treated effectively with surgery or radiation because of their size or invasion of other organs are uncommon. Topical therapies such as 5-fluorouracil, imiquimod, or photodynamic therapy have been used to treat superficial lesions. Vismodegib is modestly effective for treatment of locally advanced or metastatic basal cell carcinoma.1

MECHANISM OF ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Sonidegib (Odomzo) for Basal Cell Carcinoma
Article code: 1489c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian